21 min
Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis PeerVoice Brain & Behaviour Video
-
- Science
Visit https://www.peervoice.com/PBV860 to view the entire programme with slides. After completing “Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis”, participants will be able to: Describe the role of autoantibodies in the pathophysiology of generalised myasthenia gravis (gMG); Identify the specific autoantibodies associated with gMG and the effects they have on the neuromuscular junction (NMJ); Explain why identifying autoantibody specificity is important for optimising clinical outcomes in patients with gMG; and Use the serological autoantibody status of patients with gMG to determine which therapeutic class is most appropriate for optimising clinical outcomes.
Visit https://www.peervoice.com/PBV860 to view the entire programme with slides. After completing “Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis”, participants will be able to: Describe the role of autoantibodies in the pathophysiology of generalised myasthenia gravis (gMG); Identify the specific autoantibodies associated with gMG and the effects they have on the neuromuscular junction (NMJ); Explain why identifying autoantibody specificity is important for optimising clinical outcomes in patients with gMG; and Use the serological autoantibody status of patients with gMG to determine which therapeutic class is most appropriate for optimising clinical outcomes.
21 min